Moneycontrol
Last Updated : Jan 22, 2018 03:30 PM IST | Source: CNBC-TV18

Panacea Biotec collaborates with Serum Institute for new hexavalent vaccine for infants

Panacea Biotec in focus as the company has collaborated with Serum Institute of India for a new hexavalent vaccine for infants. In an interview with CNBC-TV18, Rajesh Jain, Joint Managing Director of the company discussed about the same.

CNBC TV18 @moneycontrolcom

Panacea Biotec in focus as the company has collaborated with Serum Institute of India for a new hexavalent vaccine for infants. In an interview with CNBC-TV18, Rajesh Jain, Joint Managing Director of the company discussed about the same.

This is a very important collaboration between two Indian companies and probably the largest in terms of potential value, which will address the immunisation needs of the developing countries including India, he said.

We introduced this vaccine in India in March 2017 and it has been taken very promptly by paediatricians in India and this collaboration is now going to take this to more than 100 countries worldwide in which both companies will manufacture this vaccine and supply to UN agencies, national governments of India as well as in the developing countries, he added.

The vaccine has a revenue potential of over USD 1 billion, said Jain.

Both companies have a capacity to supply this vaccine globally, he further mentioned.

On competition he said, this is an innovative product from Panacea Biotec so we are not expecting any competition from other companies in this space and in terms of the introduction, we are far ahead of our potential competition in the number of years.

For full interview, watch accompanying video...
First Published on Jan 22, 2018 03:30 pm

tags #Business

Loading...
Sections
Follow us on
Available On